Benzinga | Dec 15, 2021 09:23AM EST

Morgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $62

Morgan Stanley maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $74 to $62.